Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases associated with human endogenous retroviruses (HERV). The Company's main product, GNbAC1, is a humanized monoclonal antibody that is in clinical development phase IIb. GNbAC1 neutralizes the MSRV-Env protein rather than targeting the patient's immune system, and slows down or even halts the progression of multiple sclerosis. The Company's main shareholders are Eclosion2, a launching platform for new companies in the life sciences field, bioMerieux SA, which specializes in vitro diagnostics for medical and industrial applications, Institut Merieux, a private equity company, and Servier, an independent French pharmaceutical company.
|Employees (est.) (Feb 2019)||28||(+34%)|
How many employees does GeNeuro have?
GeNeuro has 28 employees.
Who are GeNeuro competitors?
Competitors of GeNeuro include Biogen, MyoKardia and Athersys.
Where is GeNeuro headquarters?
GeNeuro headquarters is located at 18 Chemin des Aulx, Plan-les-Ouates.
Where are GeNeuro offices?
GeNeuro has an office in Plan-les-Ouates.
How many offices does GeNeuro have?
GeNeuro has 1 office.